Aclaris Short Term Investments vs Long Term Debt Total Analysis
ACRS Stock | USD 3.80 0.52 12.04% |
Aclaris Therapeutics financial indicator trend analysis is way more than just evaluating Aclaris Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aclaris Therapeutics is a good investment. Please check the relationship between Aclaris Therapeutics Short Term Investments and its Long Term Debt Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.
Short Term Investments vs Long Term Debt Total
Short Term Investments vs Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aclaris Therapeutics Short Term Investments account and Long Term Debt Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Aclaris Therapeutics' Short Term Investments and Long Term Debt Total is -0.27. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Aclaris Therapeutics, assuming nothing else is changed. The correlation between historical values of Aclaris Therapeutics' Short Term Investments and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Aclaris Therapeutics are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Short Term Investments i.e., Aclaris Therapeutics' Short Term Investments and Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | -0.27 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Investments
Short Term Investments is an item under the current assets section of Aclaris Therapeutics balance sheet. It contains any investments Aclaris Therapeutics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Aclaris Therapeutics can easily liquidate in the marketplace.Long Term Debt Total
Most indicators from Aclaris Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.Discontinued Operations is likely to gain to about 167.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 21.3 M in 2024.
Aclaris Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Aclaris Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aclaris Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 98.3M | 70.8M | 251.2M | 254.6M | 197.4M | 169.3M | |
Other Current Liab | 4.2M | 8.4M | 11.6M | 10.2M | 2.2M | 2.1M | |
Total Current Liabilities | 22.4M | 14.9M | 22.9M | 21.9M | 31.0M | 16.3M | |
Total Stockholder Equity | 69.9M | 37.7M | 197.3M | 197.6M | 157.2M | 133.2M | |
Other Liab | 2.4M | 7.6M | 28.8M | 33.5M | 38.5M | 40.4M | |
Property Plant And Equipment Net | 2.5M | 1.7M | 1.3M | 1.1M | 1.6M | 1.6M | |
Net Debt | (35.3M) | (42.9M) | (26.7M) | (44.6M) | (39.5M) | (41.4M) | |
Retained Earnings | (453.5M) | (504.5M) | (595.4M) | (682.3M) | (770.8M) | (732.3M) | |
Accounts Payable | 9.9M | 5.3M | 10.0M | 10.4M | 8.9M | 7.2M | |
Cash | 35.9M | 54.1M | 27.3M | 45.3M | 39.9M | 52.9M | |
Non Current Assets Total | 14.5M | 13.3M | 46.2M | 23.0M | 68.5M | 72.0M | |
Cash And Short Term Investments | 75.0M | 54.1M | 225.7M | 229.8M | 119.1M | 137.6M | |
Common Stock Shares Outstanding | 41.3M | 42.5M | 56.7M | 65.2M | 69.8M | 38.5M | |
Short Term Investments | 39.1M | 32.1M | 164.1M | 172.3M | 79.2M | 96.3M | |
Liabilities And Stockholders Equity | 98.3M | 70.8M | 251.2M | 254.6M | 197.4M | 169.3M | |
Non Current Liabilities Total | 6.0M | 18.3M | 30.9M | 35.0M | 9.3M | 8.8M | |
Other Current Assets | 3.1M | 5.2M | 26.0M | 13.5M | 9.5M | 7.2M | |
Other Stockholder Equity | 523.5M | 542.3M | 793.0M | 880.8M | 928.1M | 495.6M | |
Total Liab | 28.4M | 33.1M | 53.9M | 57.0M | 40.2M | 36.1M | |
Property Plant And Equipment Gross | 2.5M | 1.7M | 4.7M | 5.1M | 5.8M | 6.1M | |
Total Current Assets | 83.8M | 57.5M | 205.0M | 231.6M | 128.9M | 139.1M | |
Accumulated Other Comprehensive Income | (66K) | (94K) | (224K) | (897K) | (106K) | (111.3K) | |
Property Plant Equipment | 7.2M | 1.7M | 1.3M | 1.1M | 1.3M | 1.9M | |
Net Tangible Assets | 62.7M | 30.5M | 190.3M | 190.6M | 219.2M | 135.0M | |
Non Currrent Assets Other | 4.8M | 4.5M | 3.6M | (630K) | 1.7M | 1.8M | |
Other Assets | 92K | 4.5M | 251.2M | 1.7M | 2.0M | 1.9M | |
Net Receivables | 704K | 772K | 623K | 484K | 298K | 283.1K | |
Retained Earnings Total Equity | (453.5M) | (504.5M) | (595.4M) | (682.3M) | (614.1M) | (583.4M) | |
Capital Surpluse | 523.5M | 542.3M | 793.0M | 880.8M | 1.0B | 553.9M | |
Inventory | 791K | 5.0M | (34.2M) | (12.2M) | (11.0M) | (10.5M) | |
Intangible Assets | 7.2M | 7.1M | 7.0M | 7.0M | 269K | 255.6K | |
Non Current Liabilities Other | 5.4M | 7.2M | 30.6M | 34.7M | 9.3M | 13.1M | |
Short Long Term Debt Total | 658K | 11.3M | 693K | 684K | 426K | 404.7K | |
Capital Lease Obligations | 637K | 603K | 693K | 684K | 426K | 594.9K | |
Net Invested Capital | 69.9M | 48.3M | 197.3M | 197.6M | 157.2M | 130.4M | |
Net Working Capital | 61.4M | 42.6M | 182.1M | 209.6M | 97.9M | 106.7M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.